

# Julian M M Rogasch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2786266/publications.pdf>

Version: 2024-02-01

41  
papers

454  
citations

687363

13  
h-index

752698

20  
g-index

46  
all docs

46  
docs citations

46  
times ranked

782  
citing authors

#	ARTICLE	IF	CITATIONS
1	Influences on PET Quantification and Interpretation. <i>Diagnostics</i> , 2022, 12, 451.	2.6	9
2	Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC. <i>Cancers</i> , 2022, 14, 1768.	3.7	2
3	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. <i>Cancers</i> , 2021, 13, 635.	3.7	10
4	Moving the goalposts while scoring—the dilemma posed by new PET technologies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2696-2710.	6.4	13
5	Reply to Paulo Schiavom Duarte. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3024-3025.	6.4	1
6	FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. <i>Lung Cancer</i> , 2021, 157, 66-74.	2.0	6
7	Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Outcome Assessment Applying a Prognostic Score. <i>Cancers</i> , 2021, 13, 3777.	3.7	5
8	An optimized imaging protocol for [99mTc]Tc-DPD scintigraphy and SPECT/CT quantification in cardiac transthyretin (ATTR) amyloidosis. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 2483-2496.	2.1	6
9	Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen. <i>Annals of Nuclear Medicine</i> , 2021, 35, 314-320.	2.2	6
10	Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non-Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. <i>Clinical Lung Cancer</i> , 2020, 21, 264-272.e6.	2.6	3
11	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. <i>Diagnostics</i> , 2020, 10, 732.	2.6	7
12	Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients. <i>PLoS ONE</i> , 2020, 15, e0236841.	2.5	15
13	Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition. <i>Diagnostics</i> , 2020, 10, 1084.	2.6	3
14	Reconstructed spatial resolution and contrast recovery with Bayesian penalized likelihood reconstruction (Q.Clear) for FDG-PET compared to time-of-flight (TOF) with point spread function (PSF). <i>EJNMMI Physics</i> , 2020, 7, 2.	2.7	39
15	Evaluation of T1 relaxation time in prostate cancer and benign prostate tissue using a Modified Look-Locker inversion recovery sequence. <i>Scientific Reports</i> , 2020, 10, 3121.	3.3	17
16	Contrast-enhanced ultrasound (CEUS) of cystic renal lesions in comparison to CT and MRI in a multicenter setting. <i>Clinical Hemorheology and Microcirculation</i> , 2020, 75, 419-429.	1.7	21
17	PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study. <i>F1000Research</i> , 2020, 9, 1350.	1.6	3
18	Asphericity of tumor FDG uptake in non-small cell lung cancer: reproducibility and implications for harmonization in multicenter studies. <i>EJNMMI Research</i> , 2020, 10, 134.	2.5	2

#	ARTICLE	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0236841.		0
20	Title is missing!. , 2020, 15, e0236841.		0
21	Title is missing!. , 2020, 15, e0236841.		0
22	Title is missing!. , 2020, 15, e0236841.		0
23	Interobserver variability of image-derived arterial blood SUV in whole-body FDG PET. EJNMMI Research, 2019, 9, 23.	2.5	4
24	Diffusion-weighted magnetic resonance imaging using a preclinical $^{18}\text{F}$ PET/MRI in healthy and tumor-bearing rats. EJNMMI Research, 2019, 9, 21.	2.5	5
25	The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with $^{177}\text{Lu}$ -DOTATATE. PLoS ONE, 2019, 14, e0216781.	2.5	14
26	Assessment of the tibial slope is highly dependent on the type and accuracy of the preceding acquisition. Archives of Orthopaedic and Trauma Surgery, 2019, 139, 1691-1697.	2.4	20
27	Comparison of glomerular filtration rate (GFR) with Tc-99m-DTPA and tubular extraction rate (TER) with Tc-99m-MAG3 in potential living kidney donors: Feasibility of a one-day protocol. Nuklearmedizin - NuclearMedicine, 2019, 58, 460-469.	0.7	3
28	A Novel Tracer for GD2-Positive Neuroblastoma. , 2019, 58, .		0
29	A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness. European Radiology, 2018, 28, 1949-1960.	4.5	16
30	I-123-MIBG scintigraphy in patients with neuroblastoma. Nuklearmedizin - NuclearMedicine, 2018, 57, 35-39.	0.7	2
31	Degenerative changes after posterior cruciate ligament reconstruction are irrespective of posterior knee stability: MRI-based long-term results. Archives of Orthopaedic and Trauma Surgery, 2018, 138, 377-385.	2.4	14
32	Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer, 2018, 18, 521.	2.6	39
33	Individualized risk assessment in neuroblastoma: does the tumoral metabolic activity on $^{123}\text{I}$ -MIBG SPECT predict the outcome?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2203-2212.	6.4	2
34	Detection of obstructive uropathy and assessment of differential renal function using two functional magnetic resonance urography tools. Nuklearmedizin - NuclearMedicine, 2017, 56, 39-46.	0.7	6
35	Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients. Radiation Oncology, 2017, 12, 140.	2.7	34
36	Standardized visual reading of F18-FDG-PET in patients with non-small cell lung cancer scheduled for preoperative thoracic lymph node staging. European Journal of Radiology, 2016, 85, 1345-1350.	2.6	10

#	ARTICLE	IF	CITATIONS
37	Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients. <i>European Radiology</i> , 2016, 26, 2808-2818.	4.5	10
38	The association of tumor-to-background ratios and SUVmax deviations related to point spread function and time-of-flight F18-FDG-PET/CT reconstruction in colorectal liver metastases. <i>EJNMMI Research</i> , 2015, 5, 31.	2.5	29
39	Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC. <i>BMC Cancer</i> , 2014, 14, 896.	2.6	40
40	The influence of different signal-to-background ratios on spatial resolution and F18-FDG-PET quantification using point spread function and time-of-flight reconstruction. <i>EJNMMI Physics</i> , 2014, 1, 12.	2.7	36
41	Influence of rigid coregistration of PET and CT data on metabolic volumetry: a user's perspective. <i>EJNMMI Research</i> , 2013, 3, 85.	2.5	0